U.S. Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Diagnosis (Thalassemia, Sickle Cell Disease), By Therapy, By Region, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Diagnosis
  • 1.2.3. Therapy
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Diagnosis outlook
  • 2.2.3. Therapy outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Hemoglobinopathies Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Hemoglobinopathies Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Hemoglobinopathies Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Hemoglobinopathies Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 4.4.1. Thalassemia
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Sickle cell disease
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Other Hb variants
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Hemoglobinopathies Market: Diagnosis Estimates & Trend Analysis

• 5.1. Diagnosis Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 5.4.1. Thalassemia
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2. Alpha
    • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.2. Blood test
    • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.3. Genetic test
    • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.4. Prenatal genetic test
    • 5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.5. Pre-implantation genetic test
    • 5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.6. Electrophoresis
    • 5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.7. Others
    • 5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Beta
    • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.2. Blood test
    • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.3. Genetic test
    • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.4. Prenatal genetic test
    • 5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.5. Pre-implantation genetic test
    • 5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.6. Electrophoresis
    • 5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.7. Others
    • 5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Sickle cell disease
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Blood test
    • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.3. Genetic test
    • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.4. Prenatal genetic test
    • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.5. Electrophoresis
    • 5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.6. Others
    • 5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Hb variants
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.2. Blood test
    • 5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.3. Genetic test
    • 5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.4. Prenatal genetic test
    • 5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.5. Electrophoresis
    • 5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.6. Others
    • 5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Hemoglobinopathies Market: Therapy Estimates & Trend Analysis

• 6.1. Therapy Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 6.4.1. Thalassemia
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
    • 6.4.1.2. Alpha
    • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
    • 6.4.1.2.2. Blood transfusion
    • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2.2.2. Iron chelation therapy
    • 6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2.3. Bone marrow transplant
    • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2.4. Others
    • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3. Beta
    • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
    • 6.4.1.3.2. Blood transfusion
    • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.2.2. Iron chelation therapy
    • 6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.3. Bone marrow transplant
    • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.4. Others
    • 6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Sickle Cell Disease
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.2. Blood transfusion
    • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.3. Hydroxyurea
    • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.4. Bone marrow transplant
    • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.5. Others
    • 6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. (Hb) Variants
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3.2. Blood transfusion
    • 6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3.3. Hydroxyurea
    • 6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3.4. Bone marrow transplant
    • 6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3.5. Others
    • 6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company heat map analysis, 2023
• 7.4. Company Profiles
  • 7.4.1. Sangamo Therapeutics, Inc.
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Global Blood Therapeutics, Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. bluebird bio, Inc.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Emmaus Life Sciences Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Pfizer, Inc.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Novartis AG
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Prolong Pharmaceuticals, LLC
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Bioverativ Inc.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Celgene Corp.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
• Table 3 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
• Table 4 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
• Table 5 U.S. thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
• Table 6 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
• Table 7 U.S. alpha thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
• Table 8 U.S. beta thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
• Table 9 U.S. thalassemia market, by therapy, 2018 - 2030 (USD Million)
• Table 10 U.S. alpha thalassemia market, by therapy, 2018 - 2030 (USD Million)
• Table 11 U.S. beta thalassemia market, by therapy, 2018 - 2030 (USD Million)
• Table 12 U.S. sickle cell disease market, by diagnosis, 2018 - 2030 (USD Million)
• Table 13 U.S. sickle cell disease market, by therapy, 2018 - 2030 (USD Million)
• Table 14 U.S. Hb Variants market, by diagnosis, 2018 - 2030 (USD Million)
• Table 15 U.S. hemoglobinopathies market, by region, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. hemoglobinopathies market: market outlook
• Fig. 9 U.S. hemoglobinopathies competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 U.S. hemoglobinopathies market driver impact
• Fig. 15 U.S. hemoglobinopathies market restraint impact
• Fig. 16 U.S. hemoglobinopathies market strategic initiatives analysis
• Fig. 17 U.S. hemoglobinopathies market: Type movement analysis
• Fig. 18 U.S. hemoglobinopathies market: Type outlook and key takeaways
• Fig. 19 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Sickle cell diseases market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Other Hb variants estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 U.S. hemoglobinopathies Market: Diagnosis movement Analysis
• Fig. 23 U.S. hemoglobinopathies market: Diagnosis outlook and key takeaways
• Fig. 24 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Other market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Other market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 U.S. hemoglobinopathies Market: Therapy movement Analysis
• Fig. 52 U.S. hemoglobinopathies market: Therapy outlook and key takeaways
• Fig. 53 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 U.S. hemoglobinopathies market: regional movement analysis
• Fig. 75 U.S. hemoglobinopathies market: regional outlook and key takeaways
• Fig. 76 West market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)